



Fresenius Medical Care

## P R E S S   R E L E A S E

December 10, 2003  
Oliver Heieck, Corporate Communications  
Tel.: +49-6172-6082101  
Fax: +49-6172-6082294  
e-mail: [pr-fmc@fmc-ag.de](mailto:pr-fmc@fmc-ag.de)  
[www.fmc-ag.com](http://www.fmc-ag.com)

### **2003 Dialyzer Production reaches Milestone of 50 Million Dialyzers**

**Bad Homburg, Germany – December 10, 2003** -- Fresenius Medical Care AG (“The Company”) (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS\_p), the world’s largest provider of Dialysis Products and Services, today announced that during December it produced “Dialyzer No. 50 Million”, which is the first year ever having reached production output of 50 million dialyzers annually. Over the past several years, the Company has expanded its manufacturing base and capacity in all major key markets, such as Europe, North America and recently also in Asia Pacific, specifically the market in Japan.

Over the recent years, the Company also introduced its next generation polysulfone high-flux dialyzer membrane technologies with the FX class dialyzer in the international market. Last year, the Company took a big step forward for both patients and the Company by switching its U.S. clinics to single-use (one time use) of dialyzers. Today, Fresenius Medical Care’s U.S. clinics provide single-use dialyzer treatments for their patients as part of the Company’s UltraCare™ program, which is a patient care treatment program that includes the new single-use Optiflux dialyzers as well as patient care treatment technologies with its series of 2008 dialysis machines.

At this year's American Society of Nephrology (ASN) Conference, one of the major renal conferences, which was held in San Diego on November 14 – 17, a scientific study was presented regarding the improvements in medical outcomes of single-use dialyzers compared to re-use dialyzers. This scientific study concludes that the use of new synthetic membrane dialyzers with each treatment suggests a survival advantage for patients compared to the use of dialyzers that have been clinically reprocessed (re-used).

Ben Lipps, Chief Executive Officer of Fresenius Medical Care, commented: "We are all proud to have reached this level of dialyzer production output on a global basis and we are confident that our global strategy is on the right track."

###

Fresenius Medical Care AG is the world's largest, integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,200,000 individuals worldwide. Through its network of approximately 1,540 dialysis clinics in North America, Europe, Latin America and Asia-Pacific, Fresenius Medical Care provides Dialysis Treatment to approximately 117,600 patients around the globe. Fresenius Medical Care is also the world's leading provider of Dialysis Products such as hemodialysis machines, dialyzers and related disposable products. For more information about Fresenius Medical Care, visit the Company's website at <http://www.fmc-ag.com>.

###

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG does not undertake any responsibility to update the forward-looking statements in this release.